Ann: Interim Report and Half-Year Financial Results, page-41

flotsam222

There are many frustrated investors out there who have been with Starpharma through its highs and lows. In the last three years company, if I can recall correctly, has peaked 3 times in the low to high 90 cent mark

As I recall an analayst said three years ago, he would not jump in, but wait a while.

Well from my point of view, this wait is now over

I believe we will have a great March, which will see Starpharma break $1 easily

The catalyst for this event will be

first of two payments by Astrazeneca as reward for milestones reached
completion of phase one clinical trial internally
completion of phase three clinical trial inernally
authorization by Australian government to market BV formulation in ANZ

and other positive events

In fact I believe we will have more market sensitive announcements in this month (March) than any other time in history of Starpharma's short life